Semaglutide 2.4 mg: Redefining Obesity Care in Singapore
14 Aug 2025
At the landmark launch of semaglutide 2.4 mg (Wegovy) in Singapore, leading experts—including Dr Tham Kwang Wei, Professor David Lau, Professor Walter Abhayaratna, and Dr Georgia Rigas—highlighted the urgent need to treat obesity as a chronic disease. The event saw record participation from over 1,300 healthcare professionals.
Resources
Semaglutide 2.4 mg: Redefining Obesity Care in Singapore
Semaglutide 2.4 mg: Redefining Obesity Care in Singapore